Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80%
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...
Too Old to Operate7h
PSI Outperforms CURB-65 and qSOFA in Predicting Mortality and Costs for Patients with COPD and Pneumonia
The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...
Plan to make one part of Merseyside 'smoke-free' by 2030
Since their policy announcement in 2019, becoming smokefree is a national priority for central government who set out their ...
emjreviews.com6h
Sanofi and Regeneron’s allergy drug approved as first biologic for COPD
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Pharmabiz16h
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
FDA Approves Dupixent Injections For People Struggling With COPD Symptoms
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
Yicai Global12h
China Approves World's First Targeted COPD Drug
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
Monthly Prescribing Reference5h
Dupixent Approved as Add-On Maintenance Therapy in COPD
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
pulmonologyadvisor4h
Dyspnea Impact Worse in People With PRISm vs Undiagnosed Asthma or COPD
In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.
Hurricane Helene flooding poses multiple health risks. Here's what to know.
Hurricane Helene's​ massive rains and flooding is a major health and safety risk for residents exposed to potential ...
networks.nhs.uk10h
NIHR evidence collection to help primary care teams manage long-term conditions
A National Institute for Health and Care Research (NIHR) evidence collection brings together research on whether stratified care can help primary care teams manage long-term conditions. Stratified ...